Rates of recurrent VTE were noninferior with oral apixaban compared with subcutaneous dalteparin, and rates of major bleeding were similar.
Luspatercept reduced transfusion burden compared with placebo.
PSMA PET-CT had greater sensitivity and specificity than conventional imaging for detecting pelvic nodal or distant metastases in men with high-risk prostate cancer.
Overall survival was significantly improved with matched versus unmatched therapy.
Adjuvant platinum-based chemotherapy conferred significant reductions in disease-free survival.
High-level supporting evidence for CYP2D6 genotype-guided tamoxifen dosing is still lacking.
Chelation therapy is associated with improvements in overall survival and transfusion intensity in patients with lower-risk MDS.
More cancers were diagnosed by using both techniques than by using either one alone.
Among patients with PNH clones, 66% had cytopenias and 29% had hemolytic features.
This novel approach appeared to be safe and potentially efficacious, in a small phase I trial.
Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.
Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.
Progression-free survival was prolonged with front-line brigatinib versus crizotinib.
Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.
Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.
Two-year overall survival was significantly improved with durvalumab versus placebo.
Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.
Progression-free survival was significantly longer with olaparib than with placebo.
Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.
Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.